Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,
Keywords: Everolimus, MET, RET,
#1892 Feasibility and Implication of Routine NGS Analysis in Neuroendocrine Carcinomas
Introduction: Neuroendocrine carcinomas (NECs) may arise from any organ system, exhibit various degree of differentiation and have Ki67 indices ranging from 21-100%. After first-line platin based chemotherapy, no standard treatment exists.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Knigge U, Federspiel B, Andreassen M, Kjær A, Langer S,
Keywords: neuroendocrine, neuroendocrine neoplasms, neuroendocrine carcinoma, ngs, genes, mutation, ki67, tp53, kras, braf, pik3a, pten,
Introduction: Well-differentiated Type III gastric neuroendocrine tumors (gNET III) are histologically distinct subset that have a unique pathogenesis and clinical course.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Ji Y
Introduction: The human BON-1 and QGP-1 cell lines are two models often used in pancreatic neuroendocrine tumor (PNET) research. Data on protein-changing mutations in these cell lines is lacking.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: Vandamme T
Authors: Vandamme T, Op de Beeck K, Vangestel C, Pauwels P, Van Camp G,